Compass’ psilocybin shows six-month durability in Phase III trial

Compass has already submitted for approval of its psilocybin-based therapy to the FDA following previous Phase III success. Compass has already submitted for approval of its psilocybin-based therapy to the FDA following previous Phase III success. The oral medication has shown six month durability, building on the six week data released in February. Credit: Fahroni / Shutterstock.com Compass Pathways’ psilocybin-based therapy has continued to show benefit after six months in a Phase III trial in treatment-resistant depression (TRD). Following on from six-week data previously announced in February 2026, COMP360, a synthetic, proprietary formulation of psilocybin, demonstrated rapid onset and durable…

Source: Clinical Trials Arena